by Joel Harrison
4. September 2010 14:28
Dry eye remains the most common complaint among the users of contact lenses, and it is also a generally recognised contraindication for contact lens wear, so it comes as no surprise that various companies conduct research to find effective ways of dealing with the problem. Can-Fite BioPharma has just announced opening an Investigational New Drug application (IND) with the United States Food and Drug Administration for a Phase 3 study. The study concerns one of the company’s leading drugs, CF101, and the effects of its administration in patients with moderate to severe dry eye.
The company stated that the results of an earlier Phase 2 study, consisting in oral administration of the medicine for 3 months, included the clearing of fluorescein staining of the cornea in its nasal, temporal, pupillary and inferior parts. In addition, researchers concluded that CF101 was safe and well tolerated by the subjects of the study.
The new, six-month long study will be a randomised, double-masked one, and will compare two doses of CF101 with placebo, taken by 240 subjects, who will be treated at various centres around the USA.
Subscribe